Table 1 Aurora kinase inhibitor... | American Society of Hematology

Table 1

Aurora kinase inhibitor PHA-739358 has potent effects on proliferation of leukemic cell lines

Cell line	PHA-739358, IC₅₀ (μM)	IM, IC₅₀ (μM)
K562*	0.16	0.19
BV173*	0.11	0.23
LAMA-84*	0.12	0.03
KYO-1*	0.21	0.38
KU-812*	0.05	0.03
KCL-22*	0.60	0.50
JURL-MK-1*	0.07	0.03
EM-2*	0.17	0.12
MEG-01*	0.65	0.20
HL60†	3.06	25.00
BaF3†	0.33	29.60
BaF3-p210 wt*	0.36	0.90
BaF3-p210 M351T*	0.51	1.57
BaF3-p210 E255K*	0.47	11.20
BaF3-p210 T315I*	0.12	18.39

Cell line	PHA-739358, IC₅₀ (μM)	IM, IC₅₀ (μM)
K562*	0.16	0.19
BV173*	0.11	0.23
LAMA-84*	0.12	0.03
KYO-1*	0.21	0.38
KU-812*	0.05	0.03
KCL-22*	0.60	0.50
JURL-MK-1*	0.07	0.03
EM-2*	0.17	0.12
MEG-01*	0.65	0.20
HL60†	3.06	25.00
BaF3†	0.33	29.60
BaF3-p210 wt*	0.36	0.90
BaF3-p210 M351T*	0.51	1.57
BaF3-p210 E255K*	0.47	11.20
BaF3-p210 T315I*	0.12	18.39

BCR-ABL-positive and BCR-ABL-negative cell lines were treated with PHA-739358 or IM for 48 hours. Cell viability was determined by MTT assay.

BCR-ABL-positive cells.

BCR-ABL-negative cells.